When: Retest of 50 SMA (~$240) with positive RSI divergence

Then: 25% of target position

REDUCE from current weight; enter at 0.75-1.0x benchmark with 30% initial tranche, stop at $234, require technical confirmation above 10 EMA ($248.91) with 6M+ volume before adding

• Forward EPS of $16.26 versus TTM $3.54 represents a 4.5x jump that requires execution on multiple line items: Apogee dilution, biosimilar pressure, and floating-rate debt servicing
• Post-earnings 4-5% drop is price discovery reflecting new risk profile from dilutive M&A, increased leverage, and floating-rate exposure—not irrational market behavior
• Apogee comparison to Allergan represents survivorship bias; Allergan took 6 years to integrate and only now produces diversified revenue
• AbbVie issued multi-billion-dollar floating-rate bonds creating structural interest expense risk as rates remain elevated
• 24/7 Wall Street model prices AbbVie $50 below current price—a published bear case that cannot be dismissed as market boredom
• Stock has pulled back 7.9% from late July peak with negative MACD histogram for 11+ straight sessions
• Price closed below 10 EMA at $248.91 today—a short-term distribution signal
• Current 9.8% stop distance ($24 from $244 entry) is too wide for a defensive name, encouraging hope trading over discipline
• Tighter stop at $234 sits below Bollinger lower band ($238.80) and 50-day moving average cluster
• Today's volume of 4.21M shares reflects vacuum of buyers, not necessarily accumulation

→ vs aggressive: PEG ratio of 0.40 is not mispriced—forward growth requires 4.5x EPS jump that hasn't materialized, with execution risk embedded across Apogee dilution, biosimilar headwinds, and floating-rate debt costs

→ vs aggressive: Post-earnings drop is not a gift but legitimate price discovery reflecting new risk profile from capital allocation decisions; market is forward-looking

→ vs aggressive: Apogee-Allergan comparison is survivorship bias; Allergan took 6 years of volatile integration with negative book value contribution before producing results

→ vs aggressive: Macro dismissal ignores floating-rate bond issuance—same defensive yield arbitrage praised is being eroded by rising interest expense quarterly

→ vs aggressive: Low-confidence sentiment is a data vacuum, not bullish signal; 24/7 Wall Street explicitly prices AbbVie $50 below current price as a published bear case

→ vs aggressive: Position sizing at 1.0-1.25x benchmark is overweight for a name in confirmed short-term downtrend with 11 sessions of negative MACD

→ vs aggressive: 50% initial tranche is too aggressive given stock has not reclaimed 10 EMA; 30% is appropriate starting position

→ vs aggressive: Stop at $220 allows near 10% drawdown before admitting thesis is wrong—tightening to $234 enforces capital discipline rather than hope trading

BUY (calibrated staged entry)

• Target 0.9x benchmark weight, splitting the difference between aggressive 1.0-1.25x and conservative 0.75x
• Initiate 40% of target position in the $244-248 entry zone, not 50% ahead of 10 EMA reclaim or 30% waiting for full confirmation
• Keep stop at $220, well below structural support; $234 stop would trigger on routine intraday wicks and create whipsaw
• Second tranche trigger: close above $250 on volume above 5 million shares (splitting $252 aggressive and 6M conservative)
• Final tranche reserved for successful 50 SMA retest around $240 with positive RSI divergence
• Forward P/E of 15.25 with PEG of 0.40 represents fair value with margin of safety if SKYRIZI and RINVOQ delivery continues
• Risk per share of ~$24 (10%) is acceptable for defensive position with dividend paying to wait
• Forward EPS of $16.26 vs TTM of $3.54 reflects normalization, not normal growth rate; valuation is reasonable but not screamingly cheap
• Floating-rate debt creates real income statement drag from rising interest expense; deserves position size haircut but not avoidance
• Dividend yield of 2.81% with 1.4x FCF coverage is sustainable and growing but not bulletproof if cash flow pressured
• Apogee acquisition is pipeline-stage (different from Allergan commercial-stage) making it neutral to slightly negative near-term
• Post-earnings 4-5% drop after beat is informative about market prioritizing capital structure over operating performance
• Sentiment uncertainty supports moderate rather than conviction-weighted position sizing
• Net leverage of 2.1x is manageable for AbbVie's balance sheet capacity
• Multi-quarter horizon needed to let franchise transition and post-earnings digestion work through

→ vs aggressive: PEG argument is overselling; valuation is fair but not a gift; requires SKYRIZI and RINVOQ to keep delivering

→ vs aggressive: 1.0-1.25x benchmark weight is overweight given confirmed short-term downtrend

→ vs aggressive: Post-earnings drop framing as 'purely a gift' ignores that capital structure story is now in play and needs pricing in

→ vs aggressive: Apogee 'same playbook' comparison is intellectually lazy; Apogee is pipeline-stage vs Allergan commercial-stage

→ vs aggressive: Floating-rate debt concern deserves structural position size haircut, not complete dismissal

→ vs conservative: $234 stop is structurally flawed; sits only $7 below 50 SMA support and will trigger on routine intraday wicks before meaningful damage

→ vs conservative: 0.75x benchmark weight is too light given asymmetric setup if franchise transition continues

→ vs conservative: Low retail enthusiasm framing underestimates rotation benefit into defensives in higher-for-longer rate environment

→ vs conservative: Dividend deserves more respect than given; 2.81% yield with 1.4x coverage is sustainable and provides real return while waiting

→ vs conservative: Second tranche volume trigger of 6M shares is too strict; 5M is sufficient for momentum confirmation